Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02509026 · ClinicalTrials.gov registry record · Phase 4
Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 210
- Enrollment target
NCT02509026 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 210 participants.
The verdict
NCT02509026, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 210 participants
- Enrollment target
Study Summary
The purpose of this study is to study the benefits and risks of etanercept withdrawal in patients who have achieved a significant clinical response.
Interventions
- BIOLOGICAL Etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2015-09-24 |
| Est. Completion | 2019-09-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02509026
The ClinicalTrials.gov registry entry for NCT02509026 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Etanercept is the first listed.
NCT02509026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02509026 about?
NCT02509026 is a clinical study titled "Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA". The purpose of this study is to study the benefits and risks of etanercept withdrawal in patients who have achieved a significant clinical response.
What is the current status of trial NCT02509026?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 210 participants. The study started on 2015-09-24. Estimated completion is 2019-09-06.
What interventions are being tested in trial NCT02509026?
The interventions under investigation include: Etanercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT02509026?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.